의약품 지질 기반 부형제 시장 : 규모, 점유율 및 동향 분석 보고서 - 부형제 유형별, 제품 용도별, 질환 용도별, 산업 용도별, 연령층별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Pharmaceutical Lipid-Based Excipients Market Size, Share & Trends Analysis Report By Excipient Type, By Product Applications, By Disease Application, By Industry Application, By Age Group, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

의약품 지질 기반 부형제 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 의약품 지질 기반 부형제 시장 규모는 2030년까지 24억 2,000만 달러에 이르고, 예측 기간 동안 CAGR 4.8%를 나타낼 것으로 예상됩니다. 파이프라인 후보의 87%를 차지하는 난용성 약물 후보 증가로 고급 부형제 솔루션의 채용이 진행되고 있습니다. 고체 지질 나노입자 및 자기 유화 약물전달 시스템과 같은 지질 기반 부형제는 복잡한 분자에 필수적이며 제제화 과제를 효과적으로 해결합니다. 이러한 급증은 약물의 생체이용률과 효능을 높이는 혁신적인 솔루션에 대한 제약 업계의 요구를 반영합니다.

지질 기반 부형제의 통합은 COVID-19 팬데믹학에서 강조된 바와 같이 mRNA 백신과 유전자 치료에 혁명을 가져왔습니다. 또한, 주요 의약품의 특허 부족으로 비용 효율적인 부형제에 대한 수요가 더욱 높아지고 있습니다. 이러한 요인은 현대 의약품 개발에서 지질 부형제의 변화적인 영향과 약물 전달의 혁신을 촉진하는 역할을 강조합니다.

인공지능(AI)과 제제 기술의 진보는 지질 첨가제 시장의 성장에 더욱 기여하고 있습니다. AI 주도 모델링은 지질 기반 제제를 가속화하고 예측 가능성을 높이고 시장 출시 시간을 단축합니다. 규제기관은 지질부형제에 높은 기대를 갖고 있으며, 순도와 안전특성에 주목함으로써 환자의 안전을 우선하고 궁극적으로 의약품의 품질과 효능을 확보하고 있습니다.

의약품 지질 기반 부형제 시장 : 분석 개요

• 부형제에 의하면 지질 약물 전달의 진보, 영양보조식품의 사용, 지속 가능한 성분에 대한 수요에 따라 2024년에는 유지 부형제가 총 매출의 40.5%를 차지해 시장을 독점했습니다.
• 레시틴과 인지질 부문은 예측 기간 동안 견고한 CAGR로 성장할 것으로 예측됩니다.
• 제품 용도별로는 국소용 제제가 2024년에 최대의 수익 점유율로 시장을 선도했지만, 안과 용도는 예측 기간 중에 6.7%의 가장 빠른 성장률이 예상됩니다.
• 질환별로, 지질 기반 부형제의 종양학적 용도가 2024년에 가장 큰 수익을 얻었습니다.
• 업종별로는 지질 부형제 제조업체와 보충제에 특화한 제약 기업과의 전략적 파트너십에 추진되어 영양보조식품·기타 분야가 예측 기간 중에 가장 빠른 CAGR을 기록할 전망입니다.
• 노화 관련 증상이 확산됨에 따라 노인 제품(65세 이상) 분야는 예측 기간 동안 5.0% 이상의 CAGR을 기록할 전망입니다.
• 최종 용도별로 제약 제조업체는 2024년 시장에서 지배적인 최종 사용자로 부상하여 총 매출의 64.9%를 차지했습니다.
• 2024년 4월, IOI Oleo GmbH는 화장품 산업을 위해 DYNASAN CrystalCONTROL L을 출시했습니다. 이 제품은 스틱 제형의 "블루밍" 효과에 대응하여 제품의 안정성과 미관을 향상시키고 세계적으로 걱정없는 프로세스를 실현합니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 제조업체측의 전망 : 시장의 변동 요인·동향·범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 시장 기회의 분석
  • 시장 과제 분석
• 의약품 지질 기반 부형제 시장 : 분석 도구
  • Porter's Five Forces 분석
• 고객의 요구, 문제점, 이익 분석

제4장 의약품 지질 기반 부형제 제조업체경쟁 구도

• 기업/경쟁 분류(주요 혁신자, 시장 리더, 신흥 기업)
• 지질 기반 부형제 제조업체의 기업 프로파일
  • ABITEC(ABF INGREDIENTS).
  • BASF CORPORATION
  • GATTEFOSSE
  • CORDENPHARMA
  • LIPOID GMBH
  • IOI OLEO GMBH
  • CRODA INTERNATIONAL PLC
  • EVONIK INDUSTRIES AG
  • ASHLAND
  • MERCK KGAA
• 기업의 시장 점유율 분석 보고서(2024년)
• 히트맵 분석

제5장 최종 사용자의 시점 : 시장 변동 요인·동향·범위

• 의약품 지질 기반 부형제 시장 전망 : 최종 사용자(구매자/소비자 기업)의 관점
  • 시장 성장 촉진요인 분석
  • 시장 기회의 분석
  • 시장 성장 억제요인 분석
  • 시장 과제 분석
• 의약품 지질 기반 부형제 시장 분석 도구
  • Porter's Five Forces 분석

제6장 최종 사용자 분석(바이어/소비자 기업), 경쟁 구도

• 기업/경쟁 분류(주요 혁신자, 시장 리더, 신흥 기업)
• 구매자/소비자 기업 프로파일
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VIATRIS INC.(FORMERLY MYLAN)
  • SANDOZ(A DIVISION OF NOVARTIS)
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • CIPLA LTD.
  • DR. REDDY'S LABORATORIES LTD.
  • AUROBINDO PHARMA LTD.
  • LUPIN LTD.
  • ZYDUS LIFESCIENCES LTD.(FORMERLY CADILA)
  • HIKMA PHARMACEUTICALS PLC
• Heatmap analysis

제7장 의약품 지질 기반 부형제 시장 : 부형제 유형별(2018-2030년)

• 의약품 지질 기반 부형제 시장 : 부형제 유형별 분석
• 부형제 유형별(2018-2030년)
  • 오일
  • 경화 식물성 오일
  • GMCC
  • 경질 지방
  • 중쇄중성지방(MCTS)
  • 레시틴 및 인지질
  • 올레산 나트륨
  • 카프리 카프릴 모노 디글리세리드
  • 기타 부형제의 유형

제8장 의약품 지질 기반 부형제 시장 : 제품 용도별(2018-2030년)

• 의약품 지질 기반 부형제 시장 : 제품 용도별 분석
• 제품 용도별(2018-2030년)
  • 경구 제형
  • 비경구
  • 국소 용도
  • 안과 용도
  • 좌약
  • 기타 제품 용도

제9장 의약품 지질 기반 부형제 시장 : 질환 용도별(2018-2030년)

• 의약품 지질 기반 부형제 시장 : 질환 용도별 분석
• 질환 용도별(2018-2030년)
  • 심혈관 질환
  • 신경 장애
  • 종양학
  • 대사 장애
  • 호르몬 요법
  • 감염성 질환
  • 기타 질환 용도

제10장 의약품 지질 기반 부형제 시장 : 제품 산업별(2018-2030년)

• 의약품 지질 기반 부형제 시장 : 제품 산업별 분석
• 제품 산업별(2018-2030년)
  • 의약품(OTC·RX)
  • 건강기능식품(식이 보조제 및 기타)

제11장 의약품 지질 기반 부형제 시장 : 각 연령층 제품별(2018-2030년)

• 의약품 지질 기반 부형제 시장 : 각 연령층 제품별
• 각 연령층 제품별(2018-2030년)
  • 소아용 제품(0-18세)
  • 성인용 제품(19-64세)
  • 고령자용 제품(65세 이상)

제12장 의약품 지질 기반 부형제 시장, 최종 용도별(2018-2030년)

• 의약품 지질 기반 부형제 시장 : 최종 용도 제품 분석
• 최종 용도별(2018-2030년)
  • 제약 제조업체
  • 계약 개발 및 제조 조직(CDMOS)
  • 기타

제13장 의약품 지질 기반 부형제 시장 : 지역별 추정·동향 분석

• 의약품 지질 기반 부형제 시장 : 지역별 전망
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 중국
  • 인도
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 요르단
  • 이집트
  • 이란
  • 쿠웨이트

제14장 경쟁 구도

• 시장 진출기업의 분류
• 기업시장 포지셔닝 분석/힙맵 분석
• 전략 매핑
  • 기업 합병·인수(M&A)
  • 파트너십 및 협업
  • 기타
• 기업 프로파일
  • ABITEC Corporation
  • BASF
  • Gattefosse
  • CordenPharma
  • Lipoid
  • IOI Oleo GmbH
  • Croda International
  • Evonik Industries
  • Ashland
  • Merck KGaA

KTH

영문 목차

영문목차

Pharmaceutical Lipid-based Excipients Market Growth & Trends:

The global pharmaceutical lipid-based excipients market size is anticipated to reach USD 2.42 billion by 2030 and is anticipated to expand at a CAGR of 4.8% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of poorly soluble drug candidates, representing 87% of pipeline candidates, has driven the adoption of advanced excipient solutions. Lipid-based excipients such as solid lipid nanoparticles and self-emulsifying drug delivery systems have become essential for complex molecules, addressing formulation challenges effectively. This surge reflects the pharmaceutical industry's need for innovative solutions to enhance drug bioavailability and efficacy.

The integration of lipid-based excipients has revolutionized mRNA vaccines and gene therapies, as highlighted during the COVID-19 pandemic. Moreover, the demand for cost-effective excipients has further increased due to patent expirations for major pharmaceutical drugs. These factors underscore the transformative impact of lipid excipients on modern pharmaceutical development and their role in driving innovation in drug delivery.

Advancements in artificial intelligence (AI) and formulation technologies further contribute to the growth of the lipid excipients market. AI-driven modeling accelerates lipid based formulations, enhancing predictability and reducing time-to-market. Regulatory bodies maintain high expectations for lipid excipients, prioritizing patient safety by focusing on purity and safety characteristics, ultimately ensuring the quality and effectiveness of pharmaceutical products.

Pharmaceutical Lipid-based Excipients Market Report Highlights:

• Based on excipients, oil excipients dominated the market in 2024, accounting for 40.5% of the total revenue due to advancements in lipid drug delivery, nutraceutical use, and demand for sustainable ingredients.
• The lecithin and phospholipids segment is projected to grow at a robust CAGR over the forecast period.
• Based on product applications, topical formulations led the market with the largest revenue share in 2024; however, ophthalmic applications are expected to grow at the fastest rate of 6.7% over the forecast period.
• Based on disease, oncological applications of lipid-based excipients garnered the largest revenue in 2024, aided by a growing pipeline of targeted therapies and immunotherapies for cancer.
• Based on industry, the nutraceutical (dietary supplements & others) segment is expected to witness the fastest CAGR over the forecast period, fueled by strategic partnerships between lipid excipient manufacturers and supplement-focused pharmaceutical companies.
• As aging-related conditions become more widespread, the geriatric products (65+ years) segment is expected to witness the fastest CAGR of over 5.0% over the forecast period.
• Based on end use, pharmaceutical manufacturers emerged as dominant end users in the market in 2024, accounting for 64.9% of the total revenue.
• In April 2024, IOI Oleo GmbH launched DYNASAN CrystalCONTROL L for the cosmetics industry. This product addresses the "blooming" effect in stick formulations, improving product stability and aesthetics for a worry-free process globally.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Regional Scope
  • 1.1.2 Estimates And Forecast Timeline
  • 1.1.3 Objectives
  • 1.1.4 Objective - 1
  • 1.1.5 Objective - 2
  • 1.1.6 Objective - 3
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Market Evaluation Methodology:
• 1.7 List Of Secondary Sources
• 1.8 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot (Regional)
• 2.2 Segment Snapshot (Excipient Type)
• 2.3 Segment Snapshot (Product Application)
• 2.4 Segment Snapshot (Disease Application)
• 2.5 Segment Snapshot (Product Industry & Age-based Product)
• 2.6 Segment Snapshot (Product Industry & Age-based Product)
• 2.7 Segment Snapshot (End-use)
• 2.8 Competitive Landscape

Chapter 3 Manufacturers Perspective: Market Variables, Trends, and Scope

• 3.1 Pharmaceutical Lipid-Based Excipients Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
    • 3.1.1.1 Excipient Market
  • 3.1.2 Ancillary Market Outlook
    • 3.1.2.1 Polymers Excipient Market
    • 3.1.2.2 Sugars Excipient Market
    • 3.1.2.3 Minerals Excipient Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Proliferation of Drug Candidates with Low Water Solubility and Bioavailability Challenges
    • 3.2.1.2 Growing Application of Lipid Excipients in Biologics and RNA-based Therapeutics
    • 3.2.1.3 Impact of Patent Expirations on Generic Drug Production and Lipid Excipients Demand
  • 3.2.2 Market Opportunities Analysis
    • 3.2.2.1 Expansion of Pharmaceutical Manufacturing in Emerging Markets as a Growth Opportunity for Lipid Excipients
    • 3.2.2.2 Growth of Local Manufacturers Enhancing Competition and Innovation in the Lipid Excipients Market
  • 3.2.3 Market Restraint Analysis
    • 3.2.3.1 Price Sensitivity in Emerging Markets Restricting the Adoption of Premium Lipid Excipients
    • 3.2.3.2 Market Dominance by Key Players Restricting Entry and Innovation in Lipid Excipients Sector
  • 3.2.4 Market Challenges Analysis
    • 3.2.4.1 Substantial R&D Investment Requirements for Developing Novel Lipid Excipients and Delivery Systems
    • 3.2.4.2 Global Regulatory and Compliance Complexities Adding Operational Challenges for Lipid Excipients Manufacturers
• 3.3 Pharmaceutical Lipid-Based Excipients Market Analysis Tools
  • 3.3.1 PORTER'S Five Forces Analysis
• 3.4 Customer Needs, Pains, and Gains Analysis

Chapter 4 Manufacturers Competitive Landscape of Lipid-based Excipients

• 4.1 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
• 4.2 Company Profiles for Manufacturers of Lipid Excipients
  • 4.2.1 ABITEC (ABF INGREDIENTS).
    • 4.2.1.1 Company Overview
    • 4.2.1.2 Financial Overview
    • 4.2.1.3 Product Overview
    • 4.2.1.4 Key Strategic initiatives
  • 4.2.2 BASF CORPORATION
    • 4.2.2.1 Company Overview
    • 4.2.2.2 Financial Overview
    • 4.2.2.3 Product Overview
    • 4.2.2.4 Strategic Initiatives
  • 4.2.3 GATTEFOSSE
    • 4.2.3.1 Company Overview
    • 4.2.3.2 Financial Overview
    • 4.2.3.3 Product Overview
    • 4.2.3.4 Strategic Initiatives
  • 4.2.4 CORDENPHARMA
    • 4.2.4.1 Company Overview
    • 4.2.4.2 Financial Overview
    • 4.2.4.3 Product Overview
    • 4.2.4.4 Strategic Initiatives
  • 4.2.5 LIPOID GMBH
    • 4.2.5.1 Company Overview
    • 4.2.5.2 Financial Overview
    • 4.2.5.3 product Overview
    • 4.2.5.4 Key Strategic Initiatives
  • 4.2.6 IOI OLEO GMBH
    • 4.2.6.1 Company overview
    • 4.2.6.2 Financial Overview
    • 4.2.6.3 Product Overview
    • 4.2.6.4 Strategic initiatives
  • 4.2.7 CRODA INTERNATIONAL PLC
    • 4.2.7.1 Company Overview
    • 4.2.7.2 Financial Overview
    • 4.2.7.3 Product Overview
    • 4.2.7.4 Strategic Initiatives
  • 4.2.8 EVONIK INDUSTRIES AG
    • 4.2.8.1 Company Overview
    • 4.2.8.2 Financial Overview
    • 4.2.8.3 Product Overview
    • 4.2.8.4 Strategic Initiatives
  • 4.2.9 ASHLAND
    • 4.2.9.1 Company Overview
    • 4.2.9.2 Financial Overview
    • 4.2.9.3 Product Overview
    • 4.2.9.4 Strategic Initiatives
  • 4.2.10 MERCK KGAA
    • 4.2.10.1 Company Overview
    • 4.2.10.2 Financial Overview: Thermo Fisher Scientific
    • 4.2.10.3 Product Overview
    • 4.2.10.4 Strategic Initiatives
• 4.3 Company Market Share Analysis, 2024
• 4.4 Heatmap analysis

Chapter 5 End User Perspective: Market Variables, Trends, and Scope

• 5.1 Pharmaceutical Lipid-Based Excipients Market Outlook - End User (Buyer/Consumer Companies) Perspective
  • 5.1.1 Market Driver Analysis
    • 5.1.1.1 Innovation in formulation development
    • 5.1.1.2 End user companies are formulating drugs for pediatric, geriatric, and chronic disease markets
    • 5.1.1.3 The Influence of ESG Objectives on the Adoption of Sustainable Lipid Excipients by End Users
  • 5.1.2 Market Opportunities Analysis
    • 5.1.2.1 Impact of Patent Expirations on Generic Drug Production and Lipid Excipients Demand
    • 5.1.2.2 Increasing prevalence of chronic diseases driving demand for lipid based formulations
  • 5.1.3 Market Restraint Analysis
    • 5.1.3.1 High R&D Costs, a Restraint for end use Pharmaceutical Companies Using Lipid-Based Excipients
    • 5.1.3.2 Regulatory Complexity
  • 5.1.4 Market Challenges Analysis
    • 5.1.4.1 Incompatibility with the active pharmaceutical ingredient (API)
    • 5.1.4.2 Stability and Shelf-Life Concerns
• 5.2 Pharmaceutical Lipid-Based Excipients Market Analysis Tools
  • 5.2.1 PORTER'S Five Forces Analysis

Chapter 6 End User Analysis (Buyer/Consumer Companies) Competitive Landscape

• 6.1 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
• 6.2 Buyer/Consumer Company Profiles
  • 6.2.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 6.2.1.1 Company Overview
    • 6.2.1.2 Financial Overview
    • 6.2.1.3 Product Overview
    • 6.2.1.4 Key Strategic initiatives
  • 6.2.2 VIATRIS INC. (FORMERLY MYLAN)
    • 6.2.2.1 Company Overview
    • 6.2.2.2 Financial Overview
    • 6.2.2.3 PRODUCT OVERVIEW
    • 6.2.2.4 Strategic Initiatives
  • 6.2.3 SANDOZ (A DIVISION OF NOVARTIS)
    • 6.2.3.1 Company Overview
    • 6.2.3.2 Financial Overview
    • 6.2.3.3 Product Overview
  • 6.2.4 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 6.2.4.1 Company Overview
    • 6.2.4.2 Financial Overview
    • 6.2.4.3 Product Overview
  • 6.2.5 CIPLA LTD.
    • 6.2.5.1 Company Overview
    • 6.2.5.2 Financial Overview
    • 6.2.5.3 product Overview
    • 6.2.5.4 Key Strategic Initiatives
  • 6.2.6 DR. REDDY'S LABORATORIES LTD.
    • 6.2.6.1 Company overview
    • 6.2.6.2 Financial Overview
    • 6.2.6.3 Product Overview
    • 6.2.6.4 Strategic initiatives
  • 6.2.7 AUROBINDO PHARMA LTD.
    • 6.2.7.1 Company Overview
    • 6.2.7.2 Financial Overview
    • 6.2.7.3 Product Overview
    • 6.2.7.4 Strategic Initiatives
  • 6.2.8 LUPIN LTD.
    • 6.2.8.1 Company Overview
    • 6.2.8.2 Financial Overview
    • 6.2.8.3 Product Overview
  • 6.2.9 ZYDUS LIFESCIENCES LTD. (FORMERLY CADILA)
    • 6.2.9.1 Company Overview
    • 6.2.9.2 Financial Overview
    • 6.2.9.3 Product Overview
    • 6.2.9.4 Strategic Initiatives
  • 6.2.10 HIKMA PHARMACEUTICALS PLC
    • 6.2.10.1 Company Overview
    • 6.2.10.2 Financial Overview: Hikma Pharmaceuticals PLC
    • 6.2.10.3 Product Overview
• 6.3 Heatmap analysis

Chapter 7 Pharmaceutical Lipid-Based Excipients Market, By Excipient Type, 2018 - 2030 (USD Million)

• 7.1 Pharmaceutical Lipid-Based Excipients Market: Excipient Type Analysis
• 7.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Excipient Type, 2018 - 2030 (USD Million)
  • 7.2.1 Oils
    • 7.2.1.1 Sesame Oil
    • 7.2.1.2 Soybean Oil
    • 7.2.1.3 Sunflower Oil
    • 7.2.1.4 Linseed Oil /Flaxseed Oil
    • 7.2.1.5 Safflower Oil
    • 7.2.1.6 Coconut Oil
    • 7.2.1.7 Arachis Oil / Peanut Oil
    • 7.2.1.8 Corn Oil / Maize Oil
    • 7.2.1.9 Olive Oil
    • 7.2.1.10 Almond Oil
    • 7.2.1.11 Castor Oil
    • 7.2.1.12 Cotton Seed Oil
    • 7.2.1.13 Grapeseed Oil
    • 7.2.1.14 Other Oils
  • 7.2.2 Hydrogenated Vegetable Oils
  • 7.2.3 GMCC
  • 7.2.4 Hard Fats
  • 7.2.5 Medium Chain Triglycerides (MCTS)
  • 7.2.6 Lecithin And Phospholipids
  • 7.2.7 Sodium Oleate
  • 7.2.8 Capri Caprylic Mono Diglyceride
  • 7.2.9 Other Excipient Types

Chapter 8 Pharmaceutical Lipid-Based Excipients Market, By Product Applications, 2018 - 2030 (USD Million)

• 8.1 Pharmaceutical Lipid-Based Excipients Market: Product Application Analysis
• 8.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Product Application, 2018 - 2030 (USD Million)
  • 8.2.1 Oral Formulations
    • 8.2.1.1 Softgel Capsules
    • 8.2.1.2 Solid Dosage
    • 8.2.1.3 Liquid Oral
    • 8.2.1.4 Solid Lipid Nanoparticles (Slns)
  • 8.2.2 Parenteral
    • 8.2.2.1 Small Volume Parenteral
    • 8.2.2.2 Large Volume Parenteral
  • 8.2.3 Topical Applications
    • 8.2.3.1 Creams
    • 8.2.3.2 Ointments
    • 8.2.3.3 Other Topical Applications
  • 8.2.4 Ophthalmic Applications
    • 8.2.4.1 Eye Drops
    • 8.2.4.2 Ocular Emulsions
  • 8.2.5 Suppositories
    • 8.2.5.1 Rectal Suppositories
    • 8.2.5.2 Vaginal Suppositories
    • 8.2.5.3 Other Suppositories
  • 8.2.6 Other Product Applications

Chapter 9 Pharmaceutical Lipid-Based Excipients Market, By Disease Application, 2018 - 2030 (USD Million)

• 9.1 Pharmaceutical Lipid-Based Excipients Market: Disease Application Analysis
• 9.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Disease Application, 2018 - 2030 (USD Million)
  • 9.2.1 Cardiovascular Diseases
  • 9.2.2 Neurological Disorders
  • 9.2.3 Oncology
  • 9.2.4 Metabolic Disorders
  • 9.2.5 Hormonal Therapies
  • 9.2.6 Infectious Diseases
  • 9.2.7 Other Disease Applications

Chapter 10 Pharmaceutical Lipid-Based Excipients Market, By Product Industry, 2018 - 2030 (USD Million)

• 10.1 Pharmaceutical Lipid-Based Excipients Market: Product Industry Analysis
• 10.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Product Industry, 2018 - 2030 (USD Million)
  • 10.2.1 Pharmaceutical (OTC & RX)
  • 10.2.2 Nutraceutical (Dietary Supplements & Other)

Chapter 11 Pharmaceutical Lipid-Based Excipients Market, By Age-Based Product, 2018 - 2030 (USD Million)

• 11.1 Pharmaceutical Lipid-Based Excipients Market: Age-Based Product Analysis
• 11.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Age-Based Product, 2018 - 2030 (USD Million)
  • 11.2.1 Pediatric Products (0-18 Years)
  • 11.2.2 Adult Products (19-64 Years)
  • 11.2.3 Geriatric Products (65+ Years)

Chapter 12 Pharmaceutical Lipid-Based Excipients Market, By End-Use, 2018 - 2030 (USD Million)

• 12.1 Pharmaceutical Lipid-Based Excipients Market: End-Use Product Analysis
• 12.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by End-Use, 2018 - 2030 (USD Million)
  • 12.2.1 Pharmaceutical Manufacturers
  • 12.2.2 Contract Development And Manufacturing Organizations (CDMOS)
  • 12.2.3 Other

Chapter 13 Pharmaceutical Lipid-Based Excipients Market: Regional Estimates and Trend Analysis

• 13.1 Pharmaceutical Lipid-Based Excipients Market: Regional Outlook
• 13.2 North America
  • 13.2.1 North America Pharmaceutical Lipid-Based Excipients Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.2.2 U.S.
    • 13.2.2.1 Key Country Dynamics
    • 13.2.2.2 U.S. Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 13.2.2.3 Competitive/Market Scenario
    • 13.2.2.4 Regulatory Framework
  • 13.2.3 Canada
    • 13.2.3.1 Key Country Dynamics
    • 13.2.3.2 Canada Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 13.2.3.3 Competitive/Market Scenario
    • 13.2.3.4 Regulatory Framework
  • 13.2.4 Mexico
    • 13.2.4.1 Key Country Dynamics
    • 13.2.4.2 Mexico Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.2.4.3 Competitive/Market Scenario
    • 13.2.4.4 Regulatory Framework
• 13.3 Europe
  • 13.3.1 Europe Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.3.2 UK
    • 13.3.2.1 Key Country Dynamics
    • 13.3.2.2 UK pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.2.3 Competitive/Market Scenario
    • 13.3.2.4 Regulatory Framework
  • 13.3.3 Germany
    • 13.3.3.1 Key Country Dynamics
    • 13.3.3.2 Germany pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.3.3 Competitive/Market Scenario
    • 13.3.3.4 Regulatory Framework
  • 13.3.4 France
    • 13.3.4.1 Key Country Dynamics
    • 13.3.4.2 France pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.4.3 Competitive/Market Scenario
    • 13.3.4.4 Regulatory Framework
  • 13.3.5 Italy
    • 13.3.5.1 Key Country Dynamics
    • 13.3.5.2 Italy pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.5.3 Competitive/Market Scenario
    • 13.3.5.4 Regulatory Framework
  • 13.3.6 Spain
    • 13.3.6.1 Key Country Dynamics
    • 13.3.6.2 Spain pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.6.3 Competitive/Market Scenario
    • 13.3.6.4 Regulatory Framework
  • 13.3.7 Norway
    • 13.3.7.1 Key Country Dynamics
    • 13.3.7.2 Norway Pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.7.3 Competitive/Market Scenario
    • 13.3.7.4 Regulatory Framework
  • 13.3.8 Sweden
    • 13.3.8.1 Key Country Dynamics
    • 13.3.8.2 Sweden pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.8.3 Competitive/Market Scenario
    • 13.3.8.4 Regulatory Framework
  • 13.3.9 Denmark
    • 13.3.9.1 Key Country Dynamics
    • 13.3.9.2 Denmark Pharmaceutical lipid-based excipients market estimates and forecasts, 2018 - 2030 (USD Million)
    • 13.3.9.3 Competitive/Market Scenario
    • 13.3.9.4 Regulatory Framework
  • 13.3.10 Rest Of Europe Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 13.4 Asia Pacific
  • 13.4.1 Asia Pacific Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.4.2 China
    • 13.4.2.1 Key Country Dynamics
    • 13.4.2.2 China pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.4.2.3 Competitive/Market Scenario
    • 13.4.2.4 Regulatory Framework
  • 13.4.3 India
    • 13.4.3.1 Key Country Dynamics
    • 13.4.3.2 India pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.4.3.3 Competitive/Market Scenario
    • 13.4.3.4 Regulatory Framework
  • 13.4.4 South Korea
    • 13.4.4.1 Key Country Dynamics
    • 13.4.4.2 South Korea pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.4.4.3 Competitive/Market Scenario
    • 13.4.4.4 Regulatory Framework
  • 13.4.5 Rest Of Asia Pacific Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 13.5 Latin America
  • 13.5.1 Latin America Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.5.2 Brazil
    • 13.5.2.1 Key Country Dynamics
    • 13.5.2.2 Brazil pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.5.2.3 Competitive/Market Scenario
    • 13.5.2.4 Regulatory Framework
  • 13.5.3 Argentina
    • 13.5.3.1 Key Country Dynamics
    • 13.5.3.2 Argentina pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.5.3.3 Competitive/Market Scenario
    • 13.5.3.4 Regulatory Framework
  • 13.5.4 Rest Of Latin America Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 13.6 MEA
  • 13.6.1 MEA Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.6.2 South Africa
    • 13.6.2.1 Key Country Dynamics
    • 13.6.2.2 South Africa Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.2.3 Competitive/Market Scenario
    • 13.6.2.4 Regulatory Framework
  • 13.6.3 Saudi Arabia
    • 13.6.3.1 Key Country Dynamics
    • 13.6.3.2 Saudi Arabia pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.3.3 Competitive/Market Scenario
    • 13.6.3.4 Regulatory Framework
  • 13.6.4 UAE
    • 13.6.4.1 Key Country Dynamics
    • 13.6.4.2 UAE pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.4.3 Competitive/Market Scenario
    • 13.6.4.4 Regulatory Framework
  • 13.6.5 Jordan
    • 13.6.5.1 Key Country Dynamics
    • 13.6.5.2 Jordan pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.5.3 Competitive/Market Scenario
    • 13.6.5.4 Regulatory Framework
  • 13.6.6 Egypt
    • 13.6.6.1 Key Country Dynamics
    • 13.6.6.2 Egypt pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.6.3 Competitive/Market Scenario
    • 13.6.6.4 Regulatory Framework
  • 13.6.7 Iran
    • 13.6.7.1 Key Country Dynamics
    • 13.6.7.2 Iran pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.7.3 Competitive/Market Scenario
    • 13.6.7.4 Regulatory Framework
  • 13.6.8 Kuwait
    • 13.6.8.1 Key Country Dynamics
    • 13.6.8.2 Kuwait pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.8.3 Competitive/Market Scenario
    • 13.6.8.4 Regulatory Framework
  • 13.6.9 Rest Of MEA Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 14 Competitive Landscape

• 14.1. Market Participant Categorization
• 14.2. Company Market Position Analysis/ Heap Map Analysis
• 14.3. Strategy Mapping
  • 14.3.1. Mergers & Acquisitions
  • 14.3.2. Partnerships & Collaborations
  • 14.3.3. Others
• 14.4. Company Profiles
  • 14.4.1. ABITEC Corporation
  • 14.4.2. BASF
  • 14.4.3. Gattefosse
  • 14.4.4. CordenPharma
  • 14.4.5. Lipoid
  • 14.4.6. IOI Oleo GmbH
  • 14.4.7. Croda International
  • 14.4.8. Evonik Industries
  • 14.4.9. Ashland
  • 14.4.10. Merck KGaA

관련자료